FORE Biotherapeutics Raises $67.4M to advance plixorafenib and support late-stage BRAF cancer therapy development worldwide.

Medpace's outlook turns cautious as bookings, backlog, and cancellations worsen vs. CRO peers. Click for more on MEDP stock.

Over the past several years, I have increasingly come across warnings predicting the possibility of a future civil war in the ...

NovaBridge (NBP) is rated Sell due to limited market opportunity, intense competition, and high cash burn overshadowing its ...

Extremism as a Thinking Style Extremism Beyond Ideology: Most people instinctively define “extremists” by the content of ...

Apple Music has officially revealed what it has deemed as the greatest album of all time. The music streaming service has finished sharing its list of the 100 best albums in history, by exclusively ...

Discover What’s Streaming On: Netflix‘s television library is ever-growing. Between its rapidly expanding reality universe to its smash hit original scripted series and beloved shows from HBO, NBC and ...

The best men's jewelry brands prove there’s never been so many options for fellas looking to flex some gems. As someone who’s started to consistently rock a bracelet and hoop earring myself for the ...

U.S. News compares companies to their industry peers based on a variety of company fundamentals, performance metrics and investor preferences to help you find the right stocks for your investing style ...

GIBS Business School, Bengaluru, is pleased to announce the successful conclusion of two signature annual events: HR Conclave ...